BACKGROUND: To determine whether sleep quality and fatigue associated with breast cancer adjuvant chemotherapy treatments can be improved with behavioral therapy (BT) [Individualized Sleep Promotion Plan (ISPP)] including modified stimulus control, modified sleep restriction, relaxation therapy, and sleep hygiene. METHODS: Randomized-controlled trial based on Piper Integrated Fatigue Model, 219 stagesI-IIIA breast cancer patients. Prior to the initial chemotherapy treatment, BT participants developed an ISPP plan that was regularly reinforced and revised. Controls received healthy eating information and attention. Pittsburgh Sleep Quality Index (PSQI), daily diary, actigraph, and Piper Fatigue Scale (PFS) data were collected 2 days prior, during the 7 days after each treatment, and 30 days after the last treatment. Repeated measures analysis of variance was used. RESULTS: Prior to chemotherapy, participants reported mild fatigue and fairly poor sleep quality. All variables changed over time. A group by time interaction was found for sleep quality (PSQI) improving in the BT group. Diary revealed group differences on number of awakenings, minutes awake after sleep onset, and sleep efficiency. Fatigue (PFS) was similar between groups. CONCLUSIONS: The BT group showed improved sleep quality over time and better sleep (diary). Perceptions of improved sleep quality over time are not consistently associated with diary or actigraph, or result in lower fatigue.
RCT Entities:
BACKGROUND: To determine whether sleep quality and fatigue associated with breast cancer adjuvant chemotherapy treatments can be improved with behavioral therapy (BT) [Individualized Sleep Promotion Plan (ISPP)] including modified stimulus control, modified sleep restriction, relaxation therapy, and sleep hygiene. METHODS: Randomized-controlled trial based on Piper Integrated Fatigue Model, 219 stages I-IIIA breast cancerpatients. Prior to the initial chemotherapy treatment, BT participants developed an ISPP plan that was regularly reinforced and revised. Controls received healthy eating information and attention. Pittsburgh Sleep Quality Index (PSQI), daily diary, actigraph, and Piper Fatigue Scale (PFS) data were collected 2 days prior, during the 7 days after each treatment, and 30 days after the last treatment. Repeated measures analysis of variance was used. RESULTS: Prior to chemotherapy, participants reported mild fatigue and fairly poor sleep quality. All variables changed over time. A group by time interaction was found for sleep quality (PSQI) improving in the BT group. Diary revealed group differences on number of awakenings, minutes awake after sleep onset, and sleep efficiency. Fatigue (PFS) was similar between groups. CONCLUSIONS: The BT group showed improved sleep quality over time and better sleep (diary). Perceptions of improved sleep quality over time are not consistently associated with diary or actigraph, or result in lower fatigue.
Authors: Andrea Barsevick; Susan L Beck; William N Dudley; Bob Wong; Ann M Berger; Kyra Whitmer; Tracey Newhall; Susan Brown; Katie Stewart Journal: J Pain Symptom Manage Date: 2010-06-18 Impact factor: 3.612
Authors: Nicole K Y Tang; S Tanya Lereya; Hayley Boulton; Michelle A Miller; Dieter Wolke; Francesco P Cappuccio Journal: Sleep Date: 2015-11-01 Impact factor: 5.849
Authors: Leah A Irish; Christopher E Kline; Heather E Gunn; Daniel J Buysse; Martica H Hall Journal: Sleep Med Rev Date: 2014-10-16 Impact factor: 11.609
Authors: Andrea M Barsevick; Michael R Irwin; Pamela Hinds; Andrew Miller; Ann Berger; Paul Jacobsen; Sonia Ancoli-Israel; Bryce B Reeve; Karen Mustian; Ann O'Mara; Jin-Shei Lai; Michael Fisch; David Cella Journal: J Natl Cancer Inst Date: 2013-09-18 Impact factor: 13.506
Authors: Teresa L Simoneau; Susan K Mikulich-Gilbertson; Crystal Natvig; Kristin Kilbourn; Janet Spradley; Rachel Grzywa-Cobb; Samuel Philips; Peter McSweeney; Mark L Laudenslager Journal: Psychooncology Date: 2013-02-25 Impact factor: 3.894
Authors: Ann M Berger; Brett R Kuhn; Lynne A Farr; Susanna G Von Essen; Julie Chamberlain; James C Lynch; Sangeeta Agrawal Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544